Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis

Figure 4

Meta-analysis of the incidence of neoplasms with the use of specific GLP-1 receptor agonists versus placebo or other antidiabetic treatments.